权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Engineering Viral Vector Biomanufacturing for Gene Therapy

用于基因治疗的工程病毒载体生物制造

基本信息

批准号：
2602527
负责人：
金额：
--
依托单位：
University of Sheffield
依托单位国家：
英国
项目类别：
Studentship
财政年份：
2021
资助国家：
英国
起止时间：
2021 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=studentship-2602527
关键词：
Engineering Viral Vector Biomanufacturing Gene

项目摘要

Gene therapies utilise engineered, non-pathogenic viruses (such as adeno-associated virus, AAV) as vehicles to deliver therapeutic genes to the human body that can correct genetic changes underpinning disease. This approach is potentially applicable to multiple organs of the human body, and the advanced therapies have been successfully studied in clinical trials for the treatment of, for example, a wide variety of genetic disorders and cancers. New gene therapies are beginning to be approved for use in the clinic. In 2019 73% of all viral vector clinical trials were based in the UK, 89% of which utilised AAV. It is estimated that the market for gene therapies will reach 36B USD by 2027 with a compound annual growth rate of 36%.However, viruses such as AAVs are complex molecular assemblies of numerous components which are difficult to manufacture, relying on introduction of synthetic genetic components into mammalian cells in controlled culture processes for virus manufacture, followed by purification and analysis of product quality. Low product yields and production of viruses lacking the therapeutic gene payload are endemic problems for manufacturing process development; current UK facilities for manufacturing viral vectors suitable for human treatment cannot meet demand, thus seriously hindering the translation of exciting gene therapies into clinical trials. New technology for intensified production of high quality viral gene therapies is urgently required.This project is within the scope of the EPSRC themes Manufacturing the Future and Healthcare Technologies. With respect to the latter, Developing Future Therapies is an identified. grand challenge.

基因疗法利用经过改造的非致病性病毒（如腺相关病毒AAV）作为载体，将治疗性基因输送到人体，从而纠正导致疾病的基因变化。这种方法可能适用于人体的多个器官，并且已经在临床试验中成功地研究了先进的治疗方法，例如治疗各种遗传疾病和癌症。新的基因疗法开始被批准用于临床。2019年，73%的病毒载体临床试验在英国进行，其中89%使用了AAV。预计到2027年，基因治疗市场规模将达到360亿美元，年复合增长率为36%。然而，诸如aav之类的病毒是由许多组分组成的复杂分子组装体，难以制造，依赖于在受控培养过程中将合成的遗传组分引入哺乳动物细胞以制造病毒，然后进行纯化和产品质量分析。产品产量低和生产缺乏治疗性基因载荷的病毒是制造工艺开发的地方性问题；目前英国生产适合人类治疗的病毒载体的设施无法满足需求，因此严重阻碍了将令人兴奋的基因疗法转化为临床试验。迫切需要新的技术来强化生产高质量的病毒基因疗法。该项目属于EPSRC主题“制造未来和医疗保健技术”的范围。关于后者，开发未来疗法是一个确定的。大的挑战。